Filing Flows › Health Care › Sotera Health (SHC)
Sotera Health (SHC) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 3, 2026 · Sotera Health (SHC) Q3 2026 earnings results →
Q3 2026 Revenue up 4% year over year to $325M · 18¢ of every $1 of revenue kept as net profit · operating margin 25.8%
Sotera Health made $325M in Q3 2026 (+4% Y/Y): Sterigenics $209M, Nelson Labs $60.6M, Nordion $55.0M. Operating margin 25.8%, net earnings $58.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 3, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $324.9M in Q3 2026, up 4% year over year and up 1% from the previous quarter. Sterigenics was the largest line at 64% of revenue. Sterigenics added $16.5M year over year (up 9%), 121% of the total change. Nordion declined 12%.
Gross margin was 55.6%, down 1.4 points from Q3 2025. Operating profit was $83.7M, a 25.8% margin (up 2.3 points year over year). Of the extra revenue versus Q3 2025, 80% reached operating profit, above the 23% margin then. Operating expenses fell 7% while revenue rose 4%. Net earnings were $58.4M, up 21% year over year. The effective tax rate was 30.3%.
Operating cash flow was $110.5M (up 55% year over year), 189% of net earnings. Non-cash charges added back $32.5M of depreciation and amortization and $7.7M of share-based compensation. Working capital and other items added $11.9M. Capital expenditures of $52.8M left free cash flow of $57.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 3, 2026 | $325M | +4% | 25.8% | $58.4M | $111M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $321M | +9% | 24.3% | $53.6M | $88.5M |
| Q1 2026 | 10-Q | May 5, 2026 | $280M | +10% | 15.2% | $26.6M | $29.4M |
| Q4 2025 | 10-K | Feb 24, 2026 | $303M | +5% | 23.2% | $34.8M | $103M |
| Q3 2025 | 10-Q | Nov 4, 2025 | $311M | +9% | 23.4% | $48.4M | $71.2M |
| Q2 2025 | 10-Q | Aug 8, 2025 | $294M | +6% | 6.4% | $8.0M | $57.4M |
| Q1 2025 | 10-Q | May 1, 2025 | $255M | +3% | -5.8% | −$13.3M | $55.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Sotera Health
We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. We are driven by our mission: Safeguarding Global Health ® . We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world. In 2025, our customers included over 40 of the top 50 medical device companies and nine of the top ten global pharmaceutical companies (based on revenue). Our services are an essential aspect of our customers’ manufacturing processes and supply chains, helping to ensure sterilized medical products reach healthcare practitioners and patients.
In its own words, from its 10-K, filed Feb 24, 2026.
Sotera Health against its Services-Misc Health & Allied Services, NEC peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +4% against the peers' median +5%. Operating margin: 25.8% against the peers' median 8.9%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SHC Sotera Health | Q3 2026 | $325M | +4% | 25.8% |
| DVA Davita | Q3 2026 | $3.6B | +5% | 14.0% |
| AGL agilon health | Q3 2026 | $1.5B | +6% | 1.6% |
| PGNY Progyny | Q3 2026 | $341M | +9% | 10.3% |
| VMD Viemed Healthcare | Q3 2026 | $80.7M | +12% | 8.6% |
| PARK Park Dental Partners | Q2 2026 | $66.2M | +5% | 1.9% |
| CCEL Cryo Cell International | Q3 FY26 | $7.8M | 0% | 28.0% |
| MRAI Marpai | Q2 2026 | $4.2M | -10% | -82.4% |
| PFHO Pacific Health Care Organization | Q3 2026 | $1.5M | -5% | 8.9% |
Source: Sotera Health 10-Q on SEC EDGAR · CIK 1822479 · Services-Misc Health & Allied Services, NEC
Guidance and outlook
13F: who owns SHC and who is buying
More on SHC
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Sotera Health guidance history: guided vs reported
- Sotera Health gross margin by quarter
- Sotera Health operating margin by quarter
- Sotera Health net income by quarter
- Sotera Health free cash flow by quarter
- Sotera Health capital expenditures by quarter
- Sotera Health Sterigenics revenue by quarter
- Sotera Health Nelson Labs revenue by quarter
- Sotera Health Nordion revenue by quarter